THE ANTIBODY-DRUG CONJUGATE ABT-414 DEMONSTRATES SINGLE-AGENT ANTI-CANCER ACTIVITY ACROSS A PANEL OF GBM PATIENT-DERIVED XENOGRAFTS

被引：0
|
作者：
Marin, Bianca [1 ]
Mladek, Ann [2 ]
Burgenske, Danielle [2 ]
He, Lihong [1 ]
Hu, Zeng [2 ]
Bakken, Katrina [2 ]
Carlson, Brett [2 ]
Schroeder, Mark [2 ]
Sarkaria, Jann [3 ]
机构：
[1] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA
[2] Mayo Clin, Rochester, MN USA
[3] Mayo Clin, Translat Neurooncol Lab, Rochester, MN USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
DDIS-01
引用
收藏
页码：69 / 69
页数：1
相关论文
共 37 条
  • [31] Single agent activity of U3-1402, a HER3-argeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.
    Kogawa, Takahiro
    Yonemori, Kan
    Masuda, Norikazu
    Takahashi, Shunji
    Takahashi, Masato
    Iwase, Hirotaka
    Nakayama, Takahiro
    Saeki, Toshiaki
    Toyama, Tatsuya
    Takano, Toshimi
    Onuma, Hiroshi
    Ogawa, Hayao
    Tanaka, Yoshimi
    Igari, Yoshiko
    Sugihara, Masahiro
    Vigliotti, Michele
    Yu, Channing
    Olivo, Martin Sebastian
    Ueno, Suguru
    Iwata, Hiroji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation
    Tamura, K.
    Shitara, K.
    Naito, Y.
    Shimomura, A.
    Fujiwara, Y.
    Yonemori, K.
    Shimizu, C.
    Shimoi, T.
    Kuboki, Y.
    Matsubara, N.
    Kitano, A.
    Jikoh, T.
    Fujisaki, Y.
    Yver, A.
    Doi, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] A Single Dose of a Novel Anti-Human Short Half-Life Engineered CD45-Targeted Antibody-Drug Conjugate (ADC) Is Cytoreductive on Patient-Derived Tumors and Extends Survival Beyond Standards of Care in Multiple Pre-Clinical Models of Hematologic Malignancy
    Proctor, Jennifer L.
    Gillard, Geoffrey O.
    Mikse, Oliver
    Lanieri, Leanne
    Lamothe, Tahirih L.
    Brooks, Melissa L.
    Kien, Lena
    McDonough, Sean M.
    Bhat, Anjali
    Palchaudhuri, Rahul
    Bhattarai, Prashant Raj
    Sarma, Ganapathy N.
    Jain, Nidhi
    McDonagh, Charlotte F.
    Boitano, Anthony E.
    Cooke, Michael P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S96 - S96
  • [34] Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).
    Rudin, Charles M.
    Pietanza, Maria Catherine
    Bauer, Todd Michael
    Spigel, David R.
    Ready, Neal
    Morgensztern, Daniel
    Glisson, Bonnie S.
    Byers, Lauren Averett
    Johnson, Melissa Lynne
    Burris, Howard A.
    Robert, Francisco
    Strickland, Donald K.
    Zayed, Hany
    Govindan, Ramaswamy
    Dylla, Scott
    Peng, Stanford L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [35] Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial
    Yonemori, K.
    Masuda, N.
    Takahashi, S.
    Kogawa, T.
    Nakayama, T.
    Yamamoto, Y.
    Takahashi, M.
    Toyama, T.
    Saeki, T.
    Iwata, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
    Moore, Kathleen N.
    Martin, Lainie P.
    Seward, Shelly Marie
    Bauer, Todd Michael
    O'Malley, David M.
    Perez, Raymond P.
    Oza, Amit M.
    Jeong, Woondong
    Kirby, Maurice William
    Zhou, Yinghui
    Michenzie, Mary F.
    Ponte, Joseph
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)
    Uyar, Denise
    Schilder, Russell J.
    Naumann, R. Wendel
    Braiteh, Fadi S.
    Hamilton, Erika
    Diab, Sami
    Moroney, John
    Penson, Richard T.
    Smith, Jennifer
    Abrahams, Cristina
    Palumbo, Michael
    DeAlmeida, Venita
    Matheny, Shannon
    Molina, Arturo
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
1234